44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients

Date: May 28, 2024

Camidge and Datta Detail the Career of an “Opportunistic Nomad”

Date: May 27, 2024

Drs Camidge and Datta highlight Dr Datta’s career as a surgeon-scientist and research that aims to improve systemic therapies for pancreatic cancer.

Whole Genome Sequencing for AML/MDS Risk Stratification

Date: May 27, 2024

Two clinical trials for AML or MDS are open and enrolling at Siteman Cancer Center and Washington University School of Medicine in St. Louis.

Combining Immunotherapy With Radiation Oncology in NSCLC

Date: May 27, 2024

Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.

Retrospective Data Shed Light on Prognostic Value of PD-L1 Expression in Metastatic Papillary RCC

Date: May 27, 2024

Positive PD-L1 expression was associated with worse survival in metastatic papillary renal cell carcinoma.

Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions

Date: May 27, 2024

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Non-Pharmacologic Therapies for Pain Management in Patients With Cancer: Opportunities and Challenges

Date: May 27, 2024

Janet Abrahm, MD, FACP, FAAHPM, reviews the standing of the role of integrative therapies in cancer care.

FDA Grants Priority Review to Isatuximab Combo for Newly Diagnosed, Transplant-Ineligible Myeloma

Date: May 27, 2024

The FDA granted priority review to the sBLA for isatuximab plus bortezomib/lenalidomide/dexamethasone for newly diagnosed, transplant-ineligible myeloma.

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma

Date: May 27, 2024

William Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.

Looking Ahead for Melanoma Treatment

Date: May 27, 2024

Jose Lutzky, MD, discusses clinical trials investigating novel therapies for melanoma.

Metformin Use Reduces MPN Diagnosis Risk

Date: May 26, 2024

Metformin, a type 2 diabetes drug, was found to reduce myeloproliferative neoplasm development.

Nivolumab Betters Event-Free Survival vs Chemo in Non-Small Cell Lung Cancer

Date: May 26, 2024

An interim analysis of the CheckMate 77T trial shows that nivolumab plus chemotherapy improves event-free survival in resectable non-small cell lung cancer vs chemotherapy alone.

45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?

Date: May 26, 2024

CAR T-Cell Therapy Makes its Mark in CLL

Date: May 26, 2024

David L. Porter, MD, discusses CAR T-cell therapy in chronic lymphocytic leukemia and looks towards improvements and unmet needs that remain.

End-of-Life Chemo Yields No Survival Improvement in Advanced Solid Tumors

Date: May 25, 2024

Data support revisiting goals of care conversations with patients with very advanced cancer who have significantly progressed with their disease.

Wirth Discusses What’s on the Horizon in Thyroid Cancer Research

Date: May 25, 2024

Lori J. Wirth, MD, discusses some of the emerging trends and developments that are on the horizon in the thyroid cancer space.

46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature

Date: May 25, 2024

More GVHD Complications Observed Among Patients With Obesity

Date: May 25, 2024

Valentina Ardila, MD, encouraged further research to understand the complex interplay between obesity, immune response, and transplant outcomes.

First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma

Date: May 25, 2024

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.

Induction and Transplant Outcomes Improve With Quadruplet NDMM Regimen

Date: May 24, 2024

During a Case-Based Roundtable® event, Stephanie L. Elkins, MD, discussed with participants about quadruplet vs triplet regimens and the goals of deep responses in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

Genetic Information and Patient Factors Influence BTK Inhibitor Sequencing in Frontline CLL and Beyond

Date: May 24, 2024

Sanjal Desai, MD, expands on the safety, efficacy, and sequencing of BTK inhibitors and venetoclax-based regimens in chronic lymphocytic leukemia.

Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

Date: May 24, 2024

James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.

47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?

Date: May 24, 2024

Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer

Date: May 24, 2024

Ribociclib plus endocrine therapy bested combination chemotherapy in terms of progression-free survival in HR-positive, HER2-negative advanced breast cancer.

Usmani on Indications and Timing of Autologous Transplant in Myeloma

Date: May 24, 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the specific patient subgroups for whom autologous transplant remains the best course of action for.

Dr Dorritie on the NCRI-FLAIR Trial of Ibrutinib Plus Venetoclax in Previously Untreated CLL

Date: May 24, 2024

Kathleen A. Dorritie, MD, discusses the significance of results from the phase 3 NCRI-FLAIR study in previously untreated chronic lymphocytic leukemia.

Dr Porter on Understanding Gaps in CAR T-Cell Therapy for R/R CLL

Date: May 24, 2024

David L. Porter, MD, discusses knowledge gaps regarding the optimal use of CAR T-cell therapy in relapsed/refractory chronic lymphocytic leukemia.

ARROS-1 Trial of Zidesamtinib Aims to Address Current TKI Limitations in ROS1+ NSCLC

Date: May 24, 2024

Stephen V. Liu, MD, details the phase 1/2 ARROS-1 study evaluating the selective ROS1 inhibitor zidesamtinib in patients with ROS1 fusion–positive non–small cell lung cancer.

Complete Mesocolic Excision Appears Feasible in Right Colon Cancer

Date: May 24, 2024

Treatment with complete mesocolic excision appears to reduce the length of hospital stay compared with conventional surgery in right colon cancer.

Prostate Cancer Study: More Health Benefits from Plant-Based Diet

Date: May 24, 2024

Eating more fruits, nuts and vegetables each day – along with fewer animal products – is associated with a nearly 50% reduction in the risk of prostate cancer progression.

FDA Receives Rolling NDA for Avutometinib Combo in KRAS+ Ovarian Cancer

Date: May 24, 2024

Data from the phase 2 RAMP 201 trial may support the potential accelerated approval of avutometinib/defactinib in KRAS-mutated LGSOC.